<DOC>
	<DOCNO>NCT02858453</DOCNO>
	<brief_summary>This study evaluate effect two dos oral AQX-1125 bladder pain urinary symptom subject interstitial cystitis/bladder pain syndrome . Participants receive either 100 mg AQX-1125 , 200 mg AQX-1125 placebo first 12 week study . After 12 week , participant receive either 100 mg 200 mg AQX-1125 40 week .</brief_summary>
	<brief_title>Efficacy Safety 2 Doses AQX-1125 Subjects With Interstitial Cystitis / Bladder Pain Syndrome</brief_title>
	<detailed_description>This multi-center Phase 3 trial include randomize , double-blind , placebo-controlled , parallel-group , treatment phase evaluate efficacy safety 2 dose oral AQX-1125 600 subject interstitial cystitis/bladder pain syndrome . The primary objective study evaluate effect 12 week treatment AQX-1125 ( 100 mg 200 mg ) administer daily compare placebo change Baseline Week 12 maximum daily bladder pain use standardize 11-point numerical rating scale pain score record daily electronic diary ( e-diary ) . The 12-week Treatment Period follow Extension Period 40 week . Randomization start dose occurs Baseline follow visit Week 6 Week 12 . At end Week 12 , subject randomize 40-week Extension Period . Subjects active treatment Treatment Period continue dose Extension Period , subject receive placebo Treatment Period randomize one active dose 100 mg 200 mg AQX-1125 40 week .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<criteria>Be male female , ≥18 ≤80 year age symptom bladder pain addition urinary urgency and/or urinary frequency 6 month Have clinical diagnosis , history consistent diagnosis , interstitial cystitis/bladder pain syndrome &gt; 3 month ≤20 year Must capable void independently Have undergone cystoscopy within last 36 month prior Baseline Women child bear potential must negative pregnancy test , nonlactating agree avoid pregnancy use highly effective method contraception one additional barrier method contraception screen least 28 day last dose study drug take Men must use condom sexual intercourse screen least 90 day last dose study drug take , unless surgically sterilize ( vasectomy ) Exclusion Criteria Have urinary tract infection ( UTI ) include bacterial cystitis within past 30 day Microscopic hematuria adequately evaluate per local standard care Have history chronic substance abuse , dependency abuse opiates , narcotic within last 2 year History previous procedure ( ) ( augmentation cystoplasty , cystectomy , cytolysis , botulinum toxin bladder catheterization ) significantly affect bladder function History cyclophosphamide chemical cystitis , urinary tuberculosis radiation cystitis Women : History bladder tumor ; uterine , cervical , vaginal urethral cancer Men : History prostate surgery ( transurethral resection prostate [ TURP ] , transurethral resection tumor [ TURT ] , transurethral incision prostate [ TUIP ] , transurethral needle ablation [ TUNA ] etc . ) , history prostate cancer currently treat chronic bacterial prostatitis Major surgery within 3 month prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Interstitial cystitis</keyword>
	<keyword>Bladder pain syndrome</keyword>
	<keyword>Painful bladder syndrome</keyword>
	<keyword>Interstitial Cystitis/Bladder Pain Syndrome ( IC/BPS )</keyword>
	<keyword>AQX-1125</keyword>
	<keyword>SHIP1</keyword>
	<keyword>Chronic interstitial cystitis</keyword>
</DOC>